ArticleAging2020
Stroke risk in hypertrophic cardiomyopathy patients with atrial fibrillation: a nationwide database study.
Article in Aging, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 3 syntheses or guidelines pooled it, 18 citations in OpenAlex.
- Impact of diabetes on outcomes in hypertrophic cardiomyopathy: a GRADE meta-analysis.Heart (British Cardiac Society) · 2026Pooled it
- 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.Journal of the American College of Cardiology · 2024Guideline
- Guideline
- 2026 Expert Consensus Recommendations on Hypertrophic Cardiomyopathy: A Report of the Task Force of the Taiwan Society of Cardiology.Acta Cardiologica Sinica · 2026Article
- Clinical implications and recurrence rates of first-time catheter ablation for atrial fibrillation in hypertrophic cardiomyopathy: a nationwide cohort study.European heart journal open · 2026Article
- Impact of diabetes mellitus on mortality and atrial fibrillation in hypertrophic cardiomyopathy: A systematic review and meta-analysis.World journal of diabetes · 2025Article
- Risk of Atrial Fibrillation and Stroke in Patients with Hypertrophic Obstructive Cardiomyopathy Treated by Modified Morrow Septal Myectomy: Reports of a Propensity Score Matching Cohort.Journal of cardiovascular development and disease · 2025Article
- Natural History of Hypertrophic Cardiomyopathy in Korea: A Nationwide Population-Based Retrospective Cohort Study.Journal of Korean medical science · 2025Article
- Article
- A machine learning-based predictive model for predicting early neurological deterioration in lenticulostriate atheromatous disease-related infarction.Frontiers in neuroscience · 2024Article
- Level and clinical significance of serum bFGF in patients with ischemic cardiomyopathy.American journal of translational research · 2023Article
- Clinical scoring model based on age, NIHSS, and stroke-history predicts outcome 3 months after acute ischemic stroke.Frontiers in neurology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Current treatment guidelines recommend anticoagulation for hypertrophic cardiomyopathy (HCM) with atrial fibrillation (AF) regardless of the CHA
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.